Cocrystal Prediction of Bexarotene by Graph Convolution Network and Bioavailability Improvement

Bexarotene (BEX) was approved by the FDA in 1999 for the treatment of cutaneous T-cell lymphoma (CTCL). The poor aqueous solubility causes the low bioavailability of the drug and thereby limits the clinical application. In this study, we developed a GCN-based deep learning model (CocrystalGCN) for i...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Fu, Cheng, Yinxiang, Wang, Jian-Rong, Wang, Dingyan, Zhang, Yuanyuan, Chen, Kaixian, Mei, Xuefeng, Luo, Xiaomin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611166/
https://www.ncbi.nlm.nih.gov/pubmed/36297633
http://dx.doi.org/10.3390/pharmaceutics14102198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611166/
https://www.ncbi.nlm.nih.gov/pubmed/36297633
http://dx.doi.org/10.3390/pharmaceutics14102198

Ejemplares similares